Relationship between 5-HTT gene polymorphism and treatment response in the treatment of generalized anxiety disorder patients with anti-depressants

doi:10.12092/j.issn.1009-2501.2019.08.009

Abstract

Abstract:

AIM: To explore the relationship between 5-HTT gene polymorphism and treatment response in the treatment of generalized anxiety disorder（GAD）patients with anti-depressants. METHODS: A total of 188 GAD patients who met the criteria of DSM-IV were treated with escitalopram (n=117) or venlafaxine(n=71) randomly for 8 weeks. The serum 5-HTT gene polymorphisms of all patients were detected, while Hamilton Anxiety Rating Scale (HAMA) scores were measured at baseline and after 8 weeks of treatment. A remission was defined as HAMA≤7 after 8 weeks' treatment, and a response was defined as HAMA reduction rate ≥50%. The serum 5-HTT gene polymorphisms of all healthy controls who well matched with GAD patients were also detected.RESULTS:There were no significant differences of the 5-HTT polymorphism genotypes and alleles between GAD and controls(P>0.05)．Baseline HAMA in different 5-HTT genotype had no significant differences （F=0.052，P=0.949）. The reduction of HAMA in SS,LS,LL genetypes after the treatment had no significant difference（F=0.748，P=0.475）. The reduction of HAMA in SS，LS，LL genetypes after the treatment of escitalopram had no significant difference（F=0.210，P=0.811）. The reduction of HAMA in SS，LS，LL genetypes after the treatment of venlafaxine had significant difference（F=3.505，P=0.036），the reduction of HAMA in LL genetype were higher than that in SS and LS genetypes.CONCLUSION: The 5-HTT polymorphism maybe was not associated with GAD and antidepressant clinical efficacy in GAD patients, but the efficacy of the LL genetype may be better than LS and SS genetypes after the treatment of venlafaxine.

Key words: serotonin transporter, antidepressants, generalized anxiety disorder, efficacy

CLC Number:

R749
R968

LIN Min, SHEN Zhongxia, QIAN Mincai, CUI Lijun, REN Lie, CAI Min, SHEN Xinhua. Relationship between 5-HTT gene polymorphism and treatment response in the treatment of generalized anxiety disorder patients with anti-depressants[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 903-909.

References

［1］Phillips MR, Zhang JX, Shi QC,et al.Prevalence, treatment and associated disability of mental disorders in four provinces in China during 2001-05:an epidemiological survey［J］. Lancet，2009, 373(9680): 2041-2053.
［2］Maes M, Bonifacio KL, Morelli NR, et al. Generalized anxiety disorder (GAD) and comorbid major depression with gad are characterized by enhanced nitro-oxidative stress, increased lipid peroxidation, and lowered lipid-associated antioxidant defenses［J］. Neurotox Res, 2018, 34(3):489-510.
［3］Gatt JM, Nemeroff CB, Dobsonstone C, et al. Interactions between BDNF Val66Met polymorphism and early life stress predict brain and arousal pathways to syndromal depression and anxiety［J］. Mol Psychiatry, 2009, 14(7):681-695.
［4］Gomez AF, Barthel AL, Hofmann SG. Comparing the efficacy of benzodiazepines and serotonergic anti-depressants for adults with generalized anxiety disorder: a meta-analytic review［J］. Expert Opin Pharmacother, 2018, 19(8):883-894.
［5］沈鑫华, 沈仲夏. 广泛性焦虑障碍的治疗进展［J］. 医学与哲学, 2013, 34(4):15-19.
［6］Hamon M, Blier P. Monoamine neurocircuitry in depression and strategies for new treatments［J］. Prog Neuropsychopharmacol Biol Psychiatry, 2013, 45(3):54-63.
［7］You JS, Hu SY, Chen B, et al. Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder［J］. Psychiatric Genetics, 2005, 15(1):7.
［8］李春波, 邹政, 方芳,等. 5-羟色胺转运体启动子区多态性与焦虑症的关联研究［J］. 中华行为医学与脑科学杂志, 2006, 38(1):89-89.
［9］Gottschalk MG, Domschke K.Genetics of generalized anxiety disorder and related traits［J］. Dialogues Clin Neurosci, 2017, 19(2):159-168.
［10］Lenze EJ, Goate AM, Nowotny P, et al. Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults［J］.J Clin Psychopharmacol, 2010, 30(6):672-677.
［11］Lohoff FW, Narasimhan S, Rickels K. Interaction between polymorphisms in serotonin transporter (SLC6A4) and serotonin receptor 2A (HTR2A) genes predict treatment response to venlafaxine XR in generalized anxiety disorder［J］.Pharmacogenomics J，2013, 13(5):464-469.
［12］Qian M, Shen Z, Lin M, et al. Early improvement predicts 8‐week treatment outcome in patients with generalized anxiety disorder treated with escitalopram or venlafaxine［J］. Asia-pacific Psychiatry, 2016:e12270.
［13］Jonassen R, Landro NI. Serotonin transporter polymorphisms (5-HTTLPR) in emotion processing: implications from current neurobiology［J］. Prog Neurobiol, 2014, 117(4):41-53.
［14］任淑敏, 吕少妮, 刘传新,等. 5-羟色胺转运体基因与抑郁症关系的Meta分析［J］. 中华行为医学与脑科学杂志, 2011, 20(2):167-169.
［15］Zhu J, Klein-Fedyshin M, Stevenson JM.Serotonin transporter gene polymorphisms and SSRI tolerability: review of pharmacogenetic evidence［J］.Pharmacotherapy, 2017, 37(9)：1089-1104.
［16］沈仲夏, 关铁峰, 沈鑫华,等. 艾司西酞普兰与文拉法辛缓释剂治疗广泛性焦虑障碍的对照研究［J］.中国临床药理学与治疗学, 2012, 17(10):1167-1171.
［17］Lazary J, Eszlari N, Juhasz G, et al.Genetic association analyses of the endocannabinoid system on anxious phenotype［J］.Neuropsychopharmacol Hung，2017，19(4):177-182.
［18］肖红, 姚辉, 李箕君,等. 5-HTT基因多态性与SSRIs,SNRIs类抗抑郁药治疗抑郁症临床疗效的关系研究［J］. 中国临床药理学杂志, 2004, 20(1):38-40.
［19］Serretti A, Kato M, De RD, et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients［J］. Molecular Psychiatry, 2007, 12(3):247.
［20］Lotrich FE, Pollock BG, Kirshner M, et al. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients［J］. J Psychiatry Neurosci, 2008, 33(2):123-130.
［21］Nonen S, Kato M, Takekita Y,et al.Polymorphism of rs3813034 in Serotonin transporter gene SLC6A4 Is associated with the selective serotonin and serotonin-norepinephrine reuptake inhibitor response in depressive disorder: sequencing analysis of SLC6A4［J］.J Clin Psychopharmacol，2016 36(1):27-31.

[1]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[2]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[3]	HUANG Xiaoming, DU Ye, LIN Shaoming, SHEN Guanle. Exploratory study of the influence of respiratory microbiology on the efficacy of PD-1 inhibitors monotherapy for patients with advanced non-small cell lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 66-74.
[4]	LIANG Meifang, CHEN Qingzhuang, YANG Peiqun, WANG Yong. Efficacy and safety of generic and branded atorvastatin in patients with ischemic stroke/transient ischemic attack: A real-world study [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 785-792.
[5]	YU Zefang, FAN Liju, YIN Xiaoyu, GAO Lili, DONG Zhanjun. Advances in new fast-acting antidepressants [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 595-600.
[6]	YANG Mengjiao, YUAN Hao, ZHENG Ya, WANG Yuping, GUO Qinghong. Advances in the treatment of potassium-competitive acid blockers in reflux esophagitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1190-1196.
[7]	BAO Jing, CHEN Xiaowen, XIA Liang, ZHAO Yuchen, XIA Ruixiang, XIA Hailong. Clinical efficacy and safety of ixazomib in the treatment of multiple myeloma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 782-786.
[8]	HUANG Yiting, SHEN Aizong. Clinical research progress of afatinib therapy for lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 474-480.
[9]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
[10]	LIN Rongfang, ZHENG Weiwei, LIU Yiwei, LIN Cuihong, WANG Changlian, HUANG Pinfang. Correlation of infliximab related genetic polymorphism, serum trough concentration and efficacy in patients with Crohn's disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1000-1006.
[11]	SUN Xiao, YANG Surong, LI Shanqun, WANG Yiqun. Regulation of REM sleep: Basic mechanisms and clinical drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(2): 214-220.
[12]	SHI Lili, LIU Xingan, SHAN Guoyong. Efficacy and safety of apatinib in the further line treatment for patients with advanced colorectal cancer failed after standard therapy and the preliminary analysis of efficacy predictors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(12): 1388-1394.
[13]	YIN Ziyi, WANG Feng, ZHAO Meng, ZHANG Tie, WANG Pilin. Effects of thymidine phosphorylase genetic variation on the prognosis of Her2 negative metastatic breast cancer patients treated with capecitabine based first line chemotherapy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1002-1008.
[14]	ZHU Songzhi. Therapeutic effect and related factors of human fibrinogen on traumatic traumatic coagulopathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 693-698.
[15]	GUO Liangtang, LIN Chao, SUN Yun, DAI Shengfeng, ZHANG Bingcai, CHEN Shu. Effects of metformin on patients with polycystic ovary syndrome and its effect on adipose tissue miR-25 level [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(5): 554-560.